Oncology | Novartis

From Our Labs

When it comes to cancer, there’s power in a good partner

Combinations of drugs could hold the key to overcoming some of the biggest challenges in lung and other cancers.

CancerClinical ResearchInnovationOncologyScientific Research
New data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio

Basel, November 4, 2021 — Novartis will highlight new data on Scemblix® (asciminib), recently approved by the US Food and Drug Administration, as well as its next-generation CAR-T platform and the latest research results for an array of hematology medicines at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition (…

Reimagine MedicineOncologyMedical Innovations
Discovery

Solving the puzzle of immunotherapy

From an eccentric idea to a revolution in medicine – the history of immunotherapy and a peek into its future.

CancerInnovationScientific ResearchOncology
FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia

Reimagine MedicineOncologyCancer
Sound Up for Lung Cancer

It’s time to change the conversation. Patient inspired and community led, Sound Up aims to empower people affected by lung cancer in raising the volume to vocally self-advocate.

CancerLiving With DiseaseOncologyPatient VoicesSocial Commitment
Access to Healthcare

Demystifying the science of myelodysplastic syndromes

Novartis works with visual artist Noma Bar and international patient group MDS Alliance to send a message of hope to people living with myelodysplastic syndromes.

CancerDisease AwarenessFuture of HealthcareOncologyPatient Education
Novartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer

Ad hoc announcement pursuant to Art. 53 LR

Reimagine MedicineOncologyMedical InnovationsCancerAd Hoc
Positive survival data for Novartis investigational radioligand therapy 177Lu-PSMA-617 published in The New England Journal of Medicine

Basel, June 23, 2021 — VISION data published today in The New England Journal of Medicine (NEJM) shows that 177Lu-PSMA-617 plus standard of care (SOC) significantly improved both overall survival (HR = 0.62 [95% CI: 0.52−0.74]; P<0.001; median 15.3 vs 11.3 months) and imaging-based progression-free survival (HR = 0.40 [99.2% CI: 0.29−0.57…

Reimagine MedicineOncologyMedical Innovations
Novartis presents important overall survival and quality-of-life results across solid tumor portfolio, among other key data at ESMO

Basel, August 30, 2021 — Novartis will present new data from its robust portfolio and pipeline of advanced therapeutic platforms in solid tumors, with more than 55 abstracts from Novartis-sponsored and investigator-initiated trials accepted at the upcoming European Society for Medical Oncology (ESMO) Congress 2021. The ESMO Congress will be held…

Reimagine MedicineOncologyCancer
Novartis announces first FDA filing acceptance for anti-PD-1 antibody tislelizumab for people with esophageal cancer

Basel, September 13, 2021 — Novartis today announced that the US Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for anti-PD-1 immune checkpoint inhibitor tislelizumab for the treatment of unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) in people who had received…

Reimagine MedicineOncologyMedical InnovationsCancer
Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021

Basel, September 17, 2021 — Novartis today announced positive health-related quality of life (HRQoL) data from its Phase III VISION study evaluating 177Lu-PSMA-617, an investigational targeted radioligand therapy, plus standard of care for metastatic castration-resistant prostate cancer (mCRPC) versus standard of care alone. Many patients with…

Reimagine MedicineOncologyMedical InnovationsCancer
Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)

Basel, September 17, 2021— Novartis today announced important findings from a real-world study evaluating the safety and efficacy of alpelisib for people living with PIK3CA-Related Overgrowth Spectrum (PROS) who received treatment daily for at least 24 weeks. Results from EPIK-P1 showed alpelisib effectively reduced volume of clinically…

Reimagine MedicineOncologyMedical InnovationsCancer